Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 33.50 GBp
Change Today -2.25 / -6.29%
Volume 440.5K
IMM On Other Exchanges
As of 11:35 AM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

immupharma plc (IMM) Snapshot

35.75 GBp
Previous Close
35.75 GBp
Day High
36.25 GBp
Day Low
32.25 GBp
52 Week High
10/30/14 - 66.00 GBp
52 Week Low
10/6/15 - 32.25 GBp
Market Cap
Average Volume 10 Days
-0.03 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for IMMUPHARMA PLC (IMM)

Related News

No related news articles were found.

immupharma plc (IMM) Related Businessweek News

No Related Businessweek News Found

immupharma plc (IMM) Details

ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company’s lead product candidates include the Lupuzor, which has completed Phase IIb clinical trials for the treatment of lupus, a chronic autoimmune, inflammatory disease; IPP-204106, an anti-cancer nucleolin antagonist peptide program that has completed pre-clinical and Phase I/IIa clinical trials for the treatment of cancer; IPP-201007, which is in pre-clinical development trials for the treatment of inflammatory/allergic conditions, such as asthma and rheumatoid arthritis; IPP-102199 that is in pre-clinical development trials for the treatment of moderate and severe pain; and IPP-203101, a peptide-based antibiotic, which is in pre-clinical development trials for the treatment of severe resistant hospital-acquired infections comprising methicillin-resistant staphylococcus aureus. Its discovery pipeline includes heterocyclic ureas scaffolds; and peptide to drug converting technology, which enhances the stability of peptides in plasma. ImmuPharma plc has collaboration with the Centre National de la Recherche Scientifique; Institut National de la Santé et de la Recherche Medicale; and the University of Bordeaux at the Institut Européen de Chimie et Biologie. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

10 Employees
Last Reported Date: 05/6/15
Founded in 1999

immupharma plc (IMM) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: 238.3K GBP
Co-Founder, President, Chief Science Officer ...
Total Annual Compensation: 364.9K GBP
Compensation as of Fiscal Year 2014.

immupharma plc (IMM) Key Developments

Immupharma plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended 30 June 2015

ImmuPharma Plc announced unaudited consolidated earnings results for the six months ended 30 June 2015. For the period, the company reported revenue was £13,559 compared with nil a year ago. Operating loss of £1,537,274 compared with £1,818,412 a year ago. Loss before taxation was £1,541,267 compared with £1,832,513 a year ago. Loss for the period was £1,541,267 compared with £1,833,475 a year ago. Loss attributable to equity holders of the parent was £1,541,297 compared with £1,833,475 a year ago. Basic and diluted loss per share was 1.74 pence compared with 2.23 pence a year ago. Net cash used in operating activities was £1,808,770 compared with £1,882,875 a year ago. Purchases of property, plant and equipment was £12,838 compared with £333,622 a year ago. Pre-tax loss narrowed to GBP 1.541 million from GBP 1.832 million a year ago. Research and development expenditure plunged to GBP 494,567 from GBP 820,357 in the prior year reflecting primarily the activities for the development of the Urelix peptide technology collaboration and the Nucant program.

ImmuPharma PLC Appoints Tim McCarthy as Non-Executive Chairman

ImmuPharma PLC announced the appointment of Tim McCarthy as Non-executive Chairman, with immediate effect. He is currently Chairman and Non-Executive Director of Incanthera, Harvard Healthcare and Expedeon Holdings. Mr. McCarthy is also the former Chief Executive Officer and Finance Director of Alizyme plc and Peptide Therapeutics Group plc.

ImmuPharma Plc, Annual General Meeting, May 29, 2015

ImmuPharma Plc, Annual General Meeting, May 29, 2015., at 11:00 GMT Standard Time. Location: Bircham Dyson Bell LLP.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMM:LN 33.50 GBp -2.25

IMM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMM.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 154.0x
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 153.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUPHARMA PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at